Prelude Capital Management, LLC Cytek Biosciences, Inc. Transaction History
Prelude Capital Management, LLC
- $1.57 Billion
- Q3 2024
A detailed history of Prelude Capital Management, LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 35,884 shares of CTKB stock, worth $244,728. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,884
Previous 35,884
-0.0%
Holding current value
$244,728
Previous $198,000
-0.0%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding CTKB
# of Institutions
133Shares Held
71.6MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$116 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$80.3 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$64.7 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$45.4 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$28.4 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $918M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...